NASDAQ:LGND Ligand Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. $90.58 +1.36 (+1.52%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$87.26▼$90.9950-Day Range$74.52▼$99.2752-Week Range$72.57▼$169.98Volume135,181 shsAverage Volume157,169 shsMarket Capitalization$1.53 billionP/E Ratio65.64Dividend YieldN/APrice Target$180.83 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ligand Pharmaceuticals Stock Forecast (MarketRank)Analyst RatingBuy3.00 Rating ScoreUpside/Downside99.6% Upside$180.83 Price TargetShort InterestHealthy5.38% of Shares Sold ShortDividend StrengthN/ASustainability-2.19Upright™ Environmental ScoreNews Sentiment0.62Based on 3 Articles This WeekInsider TradingAcquiring Shares$206.90 K Bought Last QuarterProj. Earnings Growth185.45%From $0.55 to $1.57 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.58 out of 5 starsMedical Sector61st out of 1,428 stocksPharmaceutical Preparations Industry18th out of 682 stocks 3.5 Analyst's Opinion Consensus RatingLigand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $180.83, Ligand Pharmaceuticals has a forecasted upside of 99.6% from its current price of $90.58.Amount of Analyst CoverageLigand Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.38% of the outstanding shares of Ligand Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently decreased by 0.60%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLigand Pharmaceuticals has received a 58.60% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Pneumococcal vaccines", "Rituximab", "Antihypertensives (C02)", "Quinolones", "Bevacizumab", and "Carfilzomib" products. See details.Environmental SustainabilityThe Environmental Impact score for Ligand Pharmaceuticals is -2.19. Previous Next 2.0 News and Social Media Coverage News SentimentLigand Pharmaceuticals has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Ligand Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for LGND on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $206,900.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.40% of the stock of Ligand Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.61% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to grow by 185.45% in the coming year, from $0.55 to $1.57 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is 65.64, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 59.44.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is 65.64, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 41.44.Price to Earnings Growth RatioLigand Pharmaceuticals has a PEG Ratio of 11.05. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Ligand Pharmaceuticals (NASDAQ:LGND)Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.Read More LGND Stock News HeadlinesJuly 1, 2022 | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 29, 2022 | finance.yahoo.comLigand Pharmaceuticals Appoints Jason Haas to its Board of DirectorsJune 17, 2022 | americanbankingnews.comBMO Capital Markets Initiates Coverage on Ligand Pharmaceuticals (NASDAQ:LGND)June 16, 2022 | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Downgraded to "Sell" at StockNews.comJune 12, 2022 | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Reaches New 1-Year Low at $77.01June 9, 2022 | finance.yahoo.comSermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical ProgramsJune 3, 2022 | finance.yahoo.comZacks.com featured highlights include Ligand Pharmaceuticals, Alarm.com Holdings, Radius Global, ADT, Madison Square GardenJune 3, 2022 | finance.yahoo.comLigand (LGND) Down 4.9% Since Last Earnings Report: Can It Rebound?May 18, 2022 | finance.yahoo.comZacks.com featured highlights include Madison Square Garden Entertainment, Materialise, InnovAge Holding, and Ligand PharmaceuticalsMay 18, 2022 | finance.yahoo.comAre Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Mixed Financials Driving The Negative Sentiment?May 17, 2022 | finance.yahoo.comDetoxify Your Holdings by Steering Clear of These 4 StocksMay 5, 2022 | finance.yahoo.comLigand (LGND) Q1 Earnings Beat, OmniAb Spin-Off on TrackMay 4, 2022 | investing.comLigand Pharma Tops Q1 EPS by 10cMay 4, 2022 | nasdaq.comLigand Pharmaceuticals Inc Q1 Earnings SummaryMay 4, 2022 | seekingalpha.comLigand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q1 2022 Results - Earnings Call TranscriptMay 4, 2022 | finance.yahoo.comLigand Reports First Quarter 2022 Financial ResultsMay 3, 2022 | seekingalpha.comLigand Pharmaceuticals Q1 2022 Earnings PreviewApril 28, 2022 | finance.yahoo.comSermonix Announces Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingApril 19, 2022 | finance.yahoo.comLigand to Report First Quarter Financial Results on May 4March 28, 2022 | seekingalpha.comLigand Pharmaceuticals: Moving Parts Keep MovingMarch 24, 2022 | money.usnews.comLigand Pharmaceuticals, Inc. - Ordinary Shares - Class BMarch 24, 2022 | finance.yahoo.comLigand To Spin-Off OmniAb Via Avista Capital-Backed SPAC MergerMarch 24, 2022 | finance.yahoo.comLigand (LGND) Inks Merger Deal With SPAC for OmniAb Spin-OffMarch 24, 2022 | finance.yahoo.comA New SPAC Deal Is a Fresh Idea for the M&A IndustryMarch 23, 2022 | seekingalpha.comLigand Pharmaceuticals to spin off OmniAb business through merger with Avista Public Acquisition Corp. IISee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:LGND CUSIP53220K50 CIK886163 Webwww.ligand.com Phone(858) 550-7500Fax858-550-1826Employees154Year FoundedN/ACompany Calendar Last Earnings5/04/2022Today7/03/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$180.83 High Stock Price Forecast$310.00 Low Stock Price Forecast$130.00 Forecasted Upside/Downside+99.6%Consensus RatingBuy Rating Score (0-4)3 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$1.379990 Trailing P/E Ratio65.64 Forward P/E Ratio164.69 P/E Growth11.05Net Income$57.14 million Net Margins9.00% Pretax Margin7.99% Return on Equity8.29% Return on Assets5.40% Debt Debt-to-Equity Ratio0.22 Current Ratio6.48 Quick Ratio5.88 Sales & Book Value Annual Sales$277.13 million Price / Sales5.51 Cash Flow$8.85 per share Price / Cash Flow10.24 Book Value$49.14 per share Price / Book1.84Miscellaneous Outstanding Shares16,860,000Free Float15,107,000Market Cap$1.53 billion OptionableOptionable Beta1.15 Ligand Pharmaceuticals Frequently Asked Questions Should I buy or sell Ligand Pharmaceuticals stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ligand Pharmaceuticals stock. View analyst ratings for Ligand Pharmaceuticals or view top-rated stocks. What is Ligand Pharmaceuticals' stock price forecast for 2022? 5 Wall Street research analysts have issued 12-month price targets for Ligand Pharmaceuticals' shares. Their LGND stock forecasts range from $130.00 to $310.00. On average, they predict Ligand Pharmaceuticals' share price to reach $180.83 in the next year. This suggests a possible upside of 99.6% from the stock's current price. View analysts' price targets for Ligand Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Ligand Pharmaceuticals' stock performed in 2022? Ligand Pharmaceuticals' stock was trading at $154.46 at the start of the year. Since then, LGND shares have decreased by 41.4% and is now trading at $90.58. View the best growth stocks for 2022 here. When is Ligand Pharmaceuticals' next earnings date? Ligand Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Ligand Pharmaceuticals. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced its earnings results on Wednesday, May, 4th. The biotechnology company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.19 by $0.04. The biotechnology company had revenue of $45.70 million for the quarter, compared to the consensus estimate of $34.21 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 8.29% and a net margin of 9.00%. The company's revenue for the quarter was down 17.2% compared to the same quarter last year. During the same period last year, the firm earned $1.03 earnings per share. View Ligand Pharmaceuticals' earnings history. What guidance has Ligand Pharmaceuticals issued on next quarter's earnings? Ligand Pharmaceuticals updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of $1.70-$2.20 for the period, compared to the consensus estimate of $3.22. The company issued revenue guidance of $147.00 million-$172.00 million, compared to the consensus revenue estimate of $162.39 million. Who are Ligand Pharmaceuticals' key executives? Ligand Pharmaceuticals' management team includes the following people: Mr. John L. Higgins, CEO & Exec. Director (Age 52, Pay $1.23M)Mr. Matthew W. Foehr, Pres & COO (Age 49, Pay $909k)Mr. Matthew E. Korenberg, Exec. VP of Fin. & CFO (Age 47, Pay $753.25k)Mr. Charles S. Berkman J.D., Sr. VP, Gen. Counsel & Sec. (Age 53, Pay $665.83k)Simon Latimer, Head of Investor RelationsMr. Todd Pettingill, Director of Corp. Devel.Ms. Audrey Warfield-Graham, Sr. VP of HRDr. Keith Marschke, Sr. VP of Biology & Scientific AffairsDr. Vincent D. Antle, Sr. VP of Technical Operations & QA - Capitsol (Age 53)Mr. Patrick Lucy, Sr. VP & CBO Protein Expression Bus. What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO? 1 employees have rated Ligand Pharmaceuticals CEO John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among Ligand Pharmaceuticals' employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Ligand Pharmaceuticals' key competitors? Some companies that are related to Ligand Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO). View all of LGND's competitors. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD). What is Ligand Pharmaceuticals' stock symbol? Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND." How do I buy shares of Ligand Pharmaceuticals? Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ligand Pharmaceuticals' stock price today? One share of LGND stock can currently be purchased for approximately $90.58. How much money does Ligand Pharmaceuticals make? Ligand Pharmaceuticals (NASDAQ:LGND) has a market capitalization of $1.53 billion and generates $277.13 million in revenue each year. The biotechnology company earns $57.14 million in net income (profit) each year or $1.379990 on an earnings per share basis. How many employees does Ligand Pharmaceuticals have? Ligand Pharmaceuticals employs 154 workers across the globe. How can I contact Ligand Pharmaceuticals? Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The official website for Ligand Pharmaceuticals is www.ligand.com. The biotechnology company can be reached via phone at (858) 550-7500, via email at investors@ligand.com, or via fax at 858-550-1826. This page (NASDAQ:LGND) was last updated on 7/3/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
